Introduction
============

Renal cancer types are the most aggressive common malignancies of all urological cancer types, amongst which clear cell renal cell carcinoma (ccRCC) is the the most prevalent ([@b1-ol-0-0-8315]). The incidence of ccRCC has increased during past 3 decades, particularly in high income countries ([@b2-ol-0-0-8315]). To date, several pathological and clinical features have been used to predict patient prognosis, including tumor size, pathological stage, tumor stage, performance status, localized symptoms and cachexia ([@b3-ol-0-0-8315]). However, few molecular biomarkers exist that may predict patient prognosis and serve as therapeutic targets, although numerous molecular biomarkers have been investigated in ccRCC ([@b4-ol-0-0-8315]--[@b5-ol-0-0-8315]). Previous studies have highlighted the mutations of BRCA1 associated protein-1 and SET domain containing 2, which are inversely correlated with the outcome of patients with ccRCC ([@b6-ol-0-0-8315]--[@b8-ol-0-0-8315]). Unfortunately, their use is so limited in clinical practice that further studies are required in order to identify the mechanism of ccRCC.

Long non-coding RNAs (lncRNAs) are a notable subtype of non-coding RNAs that are \>200 nt in length, but are unable to translate proteins ([@b9-ol-0-0-8315]). Previous years have witnessed the importance of lncRNAs in cancer research and revealed their notable impact on cancer cell biology ([@b10-ol-0-0-8315]). lncRNAs serve crucial regulatory functions in the biological processes of cancer, including chromatin modification, transcription, post-transcriptional processing and translation. Emerging evidence has indicated that lncRNAs may be potential biomarkers and therapeutic targets ([@b11-ol-0-0-8315],[@b12-ol-0-0-8315]). lncRNA Pvt1 oncogene (non-protein coding) (PVT1), located at 8q24.21, was revealed to be upregulated and regulated in the biological processes of various cancer types, including gastric, lung, pancreatic and breast cancer ([@b13-ol-0-0-8315]--[@b15-ol-0-0-8315]). However, the potential functions of PVT1 and its underlying mechanism in ccRCC remain unclear.

The present study aimed to investigate the potential biological functions of PVT1 in ccRCC and determine whether PVT1 may serve as a reliable prognostic marker for the disease. PVT1 expression in ccRCC tissues was investigated and validated using The Cancer Genome Atlas (TCGA) database. The association between PVT1 expression and clinical parameters and prognosis of ccRCC patients was also assessed. Furthermore, the function and underlying molecular mechanism of PVT1 in apoptosis and the cell cycle of ccRCC cells was evaluated.

Materials and methods
=====================

### Patient and tissue samples

A total of 40 paired ccRCC tissues and normal adjacent tissues, which were obtained from patients (30 males, 10 females; age range 31--66 years; mean age, 51 years) who underwent radical nephrectomy at Sun Yat-sen Memorial Hospital, Sun Yat-sen University (Guangzhou, China), were collected. Patients who had received any chemotherapy or targeted treatments were excluded. The pathological features of the samples were confirmed by pathologists at Sun Yat-sen Memorial Hospital. All tissues were stored at −80°C immediately after surgery for reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. All tissue samples were collected with written informed consent from all patients and the study was ethically approved by the Ethic Review Committee of Sun Yat-sen Memorial Hospital.

### ccRCC data from TCGA database

The clinical and pathological information of 517 patients with ccRCC were downloaded from TCGA database (<http://cancergenome.nih.gov/>) ([@b16-ol-0-0-8315]). TCGA gene expression profile was measured using the Illumina HiSeq 2000 RNA Sequencing platform (Illumina, Inc., San Diego, CA, USA). RNA-Seq by Expectation-Maximization (RSEM software v1.3.0; provided by the University of Wisconsin, Madison, WI, USA) normalized count data was used in this study. Copy number alterations were estimated by Genomics Identification of Significant Targets in Cancer 2.0 (GISTIC 2.0; provided by the Broad Institute of MIT and Harvard, Cambridge, MA, USA) ([@b17-ol-0-0-8315]), which defined the copy-number alteration of each gene as −2, −1, 0, 1 or 2, representing homozygous deletion, heterozygous deletion, diploid normal copy number, low-level amplification (gain) and high-level amplification, respectively. For analysis, the amplification and gain groups were combined and the homozygous and heterozygous groups were also combined. The RNA sequences of 448 ccRCC tissues were downloaded from the Atlas of Noncoding RNAs in Cancer (TANRIC) database (<http://ibl.mdanderson.org/tanric/_design/basic/index.html>). The patients were divided into high and low PVT1 expression groups. The median value of PVT1 expression (0.803) was used as the cut-off value.

### Cell culture

RCC cell lines, including 786-O, Caki-1, ACHN and 769-P, and the human normal kidney cell line HK-2 were obtained from the American Tissue Culture Collection (ATCC; Manassas, VA, USA). 786-O and 769-P cells were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS; Hyclone; GE Healthcare Life Sciences, Logan, UT, USA). Caki-1 cells were cultured in ATCC-formulated McCoy\'s 5a Medium Modified medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% heat-inactivated FBS. ACHN cells were cultured in Dulbecco\'s modified eagle\'s medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% heat-inactivated FBS. HK-2 cells were cultured in keratinocyte-SFM (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% heat-inactivated FBS. All cells were incubated at 37°C with 5% CO~2~ once seeded. The medium was replaced every 2 days.

### Small interfering RNA (siRNA) transfection and RNA extraction

Using Lipofectamine^®^ RNAiMAX (Invitrogen; Thermo Fisher Scientific, Inc.), ccRCC cells (786-O and Caki-1) were transfected with siRNA at 37°C for 2 days according to the manufacturer\'s protocol. A total of 1×10^5^ ccRCC cells and 5 µl siRNA per well was used in each transfection in a 6-well plate. siRNAs were obtained from Shanghai GenePharma Co., Ltd. (Shanghai, China). The siRNA sequences were as follows: Si-PVT1a, 5′-CAGCCAUCAUGAUGGUACUTT-3′ and si-PVT1b, 5′-GGCACAUUUCAGGAUACUATT−3′. Negative control siRNA for PVT1, 5′-UUCUCCGAACGUGUCACGUTT-3′. Total RNA was extracted at 2 days post-transfection using TRIzol reagent (Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol.

### Cell proliferation assay

ccRCC Cells (786-O and Caki-1) transfected with si-PVT1 and negative control were harvested at 24 h post-transfection and 1×10^3^ cells were cultured on 96-well plates. Cells were incubated with CellTiter 96^®^ Aqueous One Solution Reagent kit (MTS; Promega Corporation, Madison, WI, USA) at 37°C for 3 h and assessed every 24 h for 5 days according to the manufacturer\'s protocol. Absorbance was measured with the multifunctional microplate reader SpectraMax M5 (Molecular Devices, LLC, Sunnyvale, CA, USA) at 490 nm.

### Flow cytometry analysis

ccRCC Cells (786-O and Caki-1) transfected with si-PVT1 and negative control were harvested at 48 h post-transfection. A total of 2×10^5^ cells for each analysis of apoptosis were stained at room temperature for 15 min with fluorescein isothiocyanate-Annexin V and propidium iodide (Nanjing KeyGen Biotech Co., Ltd., Nanjing, China) and analyzed using the FACSVerse flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). Early apoptotic cells were assessed and compared. A total of 1×10^5^ cells for each cell cycle analysis were fixed in 75% ethanol at 4°C overnight and then stained with propidium iodide at room temperature for 15 min using a cell cycle detection kit (Nanjing KeyGen Biotech, Co., Ltd.) according to the manufacturer\'s protocol. The percentages of cells in the G~0~/G~1~, S and G~2~/M phases were assessed within 4 h. The acquired data were analyzed using FlowJo 10.0 (FlowJo LLC, Ashland, OR, USA).

### RT-qPCR

Total RNA of ccRCC cells (786-O and Caki-1) was extracted at 2 days post-transfection using TRIzol reagent (Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. Total RNA was reverse transcribed into cDNA using the PrimeScript™ RT Master mix (Takara Biotechnology Co., Ltd., Dalian, China). RT-qPCR was performed using SYBR-Green PCR Master mix (Roche Diagnostics, Basel, Switzerland) with the Roche LightCycler 480 (Roche Diagnostics). GAPDH was used as the internal control. The RT-qPCR reaction included a preincubation step (95°C for 300 sec), and 40 cycles of amplification step (95°C for 15 sec, 56°C for 15 sec and 72°C for 15 sec), a melting step (95°C for 10 sec, 65°C for 60 sec, 97°C for 1 sec) and a cooling step (37°C for 30 sec). The 2^−ΔΔCq^ method was used to compare expression ([@b18-ol-0-0-8315]). The sequences of the primers used are as follows: GAPDH sense, 5′-GAGCCAAAAGGGTCATCATCTC-3′ and antisense, 5′-GGTCATGAGTCCTTCCACGATAC-3′; PVT1 sense, 5′-CATCCGGCGCTCAGCT-3′ and antisense, 5′-TCATGATGGCTGTATGTGCCA−3′; EGFR sense, 5′-CGGGACATAGTCAGCAGTG-3′ and antisense, 5′-GCTGGGCACAGATGATTTTG-3′; MYC proto-oncogene, bHLH transcription factor (MYC) sense, 5′-CTTCTCTCCGTCCTCGGATTCT-3′ and antisense, 5′-GAAGGTGATCCAG-3′; protein kinase B (AKT) sense, 5′-ACGGGCACATTAAGATCACA-3′ and antisense, 5′-TGCCGCAAAAGGTCTTCATG-3′; cyclin D1 sense, 5′-GAAGGTGATCCAG-3′ and antisense, 5′-GGCGGATTGGAAATGAACTT-3′; and p21 sense, 5′-CGATGCCAACCTCCTCAACGA-3′ and anti-sense, 5′-CATCCGGCGCTCAGCT-3′.

### Western blot analysis

A total of 1×10^6^ ccRCC cells (786-O and Caki-1) were harvested at 48 h post-transfection and lysed with radioimmunoprecipitation assay protein extraction reagent (Beyotime Institute of Biotechnology, Haimen, China) supplemented with a protease inhibitor cocktail (Roche Diagnostics). The total protein concentration was measured using a Bicinchoninic Acid Protein Assay kit (Thermo Fisher Scientific, Inc., Waltham, MA, USA) with Multiskan MK3 (Thermo Fisher Scientific, Inc., Waltham, MA, USA). A total of 50 µg protein was added to each panel of 10 (for cyclin D1, Bax, p21, Myc, AKT and p-AKT) or 7.5% (for PARP and EGFR) sodium dodecyl sulfate-polyacrylamide gel according to the molecular weight of the targeted protein. Protein was transferred onto 0.22-µm nitrocellulose membranes (EMD Millipore, Billerica, MA, USA) following electrophoresis. The membranes were blocked with 5% skimmed milk at room temperature for 1 h, followed by incubation with the primary antibodies at 4°C overnight. The membranes were then incubated with corresponding horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (sc-2004; 1:5,000; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) at room temperature for 1 h. Primary antibodies (1:1,000 dilution) were against PARP (cat. no. 9532), EGFR (cat. no. 2085), MYC (cat. no. 13987), p21 (cat. no. 2947), cyclin D1 (cat. no. 2922), Bax (cat. no. 5023), AKT (cat. no. 4685) and p-AKT (cat. no. 4060; Cell Signaling Technology, Inc., Danvers, MA, USA). GAPDH was used as the reference gene for EGFR, AKT, MYC and p-AKT, and β-tubulin was used as the reference gene for PARP, cyclin D1, Bax and p21.

### Statistical analysis

χ^2^ or Kruskal-Wallis tests were used to analyze the association between the expression of PVT1 and the clinicopathological parameters. The Kaplan-Meier method and log-rank test were used for survival analyses. P\<0.05 was considered to indicate a statistically significant difference. Statistical analyses were performed using SPSS software 17.0 (SPSS Inc., Chicago, IL, USA). All these experiments were performed three times.

Results
=======

### PVT1 copy number variant in ccRCC affects overall survival

Of the 517 ccRCC cases selected from TCGA, 70 cases were identified with PVT1 gain/amplification. Next, the association between PVT1 copy number and patient prognosis was analyzed. Kaplan-Meier analysis revealed that patients with PVT1 gain experienced significantly worse overall survival compared with patients without PVT1 gain (log-rank, P\<0.01; [Fig. 1](#f1-ol-0-0-8315){ref-type="fig"}).

### PVT1 is upregulated in ccRCC tissues

In order to investigate the role of PVT1 in ccRCC, the expression of PVT1 in 40 paired ccRCC tissues and normal adjacent tissues was examined using RT-qPCR. A fold change of \>1.5 was designated as upregulated, and the results revealed that PVT1 was upregulated in 33 (82.5%) of ccRCC tissue cases compared with normal adjacent tissues ([Fig. 2A](#f2-ol-0-0-8315){ref-type="fig"}). As presented in [Fig. 2B](#f2-ol-0-0-8315){ref-type="fig"}, the mean expression of PVT1 was significantly higher in tumor tissues compared with that in adjacent normal tissues (P\<0.001).

To further validate the expression of PVT1 in ccRCC, PVT1 RNA-seq expression values from the TCGA database were analyzed. It was identified that PVT1 was significantly upregulated in ccRCC tissues (n=448) compared with that in normal kidney tissues (n=67) ([Fig. 2C](#f2-ol-0-0-8315){ref-type="fig"}).

### PVT1 expression is associated with the poor prognosis of patients with ccRCC

Subsequently, the association between PVT1 expression and clinical characteristics was analyzed. The results revealed that PVT1 expression was significantly associated with T stage (P\<0.001), M stage (P=0.024), AJCC stage (P\<0.001) and patient age (P=0.018) ([Table I](#tI-ol-0-0-8315){ref-type="table"}). No significant association was identified between PVT1 expression and patient sex, N stage and tumor grade. Next, the association between PVT1 expression and the prognosis of patients with ccRCC was assessed. The patients with ccRCC were separated into the high PVT1 expression group (n=224) and the low PVT1 expression group (n=224) according to PVT1 expression, and Kaplan-Meier analysis was performed. The result revealed that the overall survival time was significantly shorter in the high PVT1 expression group compared with that in the low PVT1 expression group (log-rank, P\<0.01; [Fig. 2D](#f2-ol-0-0-8315){ref-type="fig"}).

### Knockdown of PVT1 significantly inhibits the proliferation of ccRCC cells

In order to investigate the potential biological functions of PVT1 in ccRCC, the expression of PVT1 in ccRCC cell lines (786-O, Caki-1, ACHN and 769-P) and one normal kidney cell line (HK-2) was examined using RT-qPCR. The results revealed that PVT1 expression was significantly higher in ccRCC cells compared with that in HK-2 cells ([Fig. 3A](#f3-ol-0-0-8315){ref-type="fig"}). 786-O and Caki-1 cells were then transfected with si-PVT1s or si-NC using Lipofectamine RNAiMAX Transfection reagent, and the transfection efficiency was tested using RT-qPCR. The results revealed that the expression of PVT1 was significantly reduced in cells transfected with si-PVT1a and si-PVT1b compared with that in cells transfected with si-NC ([Fig. 3B](#f3-ol-0-0-8315){ref-type="fig"}). Next, an MTS assay was performed to examine the effect of PVT1 on the proliferation of the ccRCC cells. The MTS assay revealed that the knockdown of PVT1 significantly inhibited the proliferation of 786-O and Caki-1 cells in a time-dependent manner compared with cells in the NC group ([Fig. 3C](#f3-ol-0-0-8315){ref-type="fig"}).

### Knockdown of PVT1 significantly induces apoptosis and promotes cell cycle arrest in ccRCC cells

To further investigate the effect of PVT1 on the growth of ccRCC cells, cell apoptosis analysis and cell cycle analysis were performed using flow cytometry. Cell apoptosis analysis indicated that the knockdown of PVT1 significantly increased the apoptosis rate in 786-O and Caki-1 cells, most notably in 786-O si-PVT1a group compared with the NC group (P\<0.05; [Fig. 3D](#f3-ol-0-0-8315){ref-type="fig"}). Cell cycle analysis revealed that the knockdown of PVT1 also significantly promoted cell cycle arrest at the G0/G1 phase compared with the normal control (P\<0.05; [Fig. 3E](#f3-ol-0-0-8315){ref-type="fig"}). No significant difference in G1 phase was found between si-PVT1a and si-PVT1b.

Next, western blotting was performed to support the results of flow cytometry. The results demonstrated that the knockdown of PVT1 increased the level of Bax and the cleavage of PARP, which serve notable functions in the activation of cell apoptosis. Meanwhile, the knockdown of PVT1 decreased the level of cyclin D1, a major mediator of the cell cycle, and increased the level of p21 ([Fig. 4](#f4-ol-0-0-8315){ref-type="fig"}).

### PVT1 regulates the activation of the EGFR pathway in ccRCC cells

To investigate the underlying molecular mechanisms of PVT1 function, a potential pathway involved in cell proliferation was investigated. As EGFR pathways serve a notable role in the cell proliferation, apoptosis and cell cycle of ccRCC ([@b19-ol-0-0-8315],[@b20-ol-0-0-8315]), the mRNA and protein expression levels of EGFR following the transfection of si-PVT1a and b and si-NC were investigated. The results demonstrated that the mRNA expression level of EGFR was significantly downregulated following the knockdown of PVT1 compared with that of the NC ([Fig. 5A](#f5-ol-0-0-8315){ref-type="fig"}), and the protein expression was also notably downregulated ([Fig. 5B](#f5-ol-0-0-8315){ref-type="fig"}). Furthermore, AKT and MYC, the downstream proteins of EGFR, were detected at the mRNA and protein level following the knockdown of PVT1. It was revealed that the mRNA expression levels of AKT and MYC were significantly downregulated in si-PVT1 transfected groups compared with that in the NC groups ([Fig. 5A](#f5-ol-0-0-8315){ref-type="fig"}), and the protein expression of AKT, phosphorylated (p-)AKT and MYC in cells transfected with si-PTV1 were notably downregulated compared with that in the NC groups ([Fig. 5B](#f5-ol-0-0-8315){ref-type="fig"}). The results indicated that PVT1 may potentially regulate cell proliferation, apoptosis and the cell cycle of ccRCC cells through the activation of the EGFR pathway.

Discussion
==========

Emerging evidence has revealed that lncRNAs are of great importance in cell development and human diseases ([@b21-ol-0-0-8315]--[@b23-ol-0-0-8315]). lncRNAs have different expression patterns in different diseases, and their aberrant expression may be involved in the pathophysiology of various diseases ([@b24-ol-0-0-8315]). Studies have demonstrated that lncRNAs may be involved in the progression of various cancer types, including breast and lung cancer ([@b13-ol-0-0-8315],[@b18-ol-0-0-8315]). To date, only a few lncRNAs have been studied in renal cancer. Zhang *et al* ([@b25-ol-0-0-8315]) identified that the overexpression of metastasis associated lung adenocarcinoma transcript 1 (non-protein coding) (MALAT1) may predict the poor prognosis of patients with renal cancer, and Hirata *et al* ([@b26-ol-0-0-8315]) demonstrated that MALAT1 promoted tumorigenesis through enhancer of zeste homolog 2. The functions of growth arrest-specific 5 ([@b27-ol-0-0-8315]), neuroblastoma-associated transcript 1 ([@b28-ol-0-0-8315]) and HOX transcript antisense RNA ([@b29-ol-0-0-8315]) in the progression of ccRCC were also investigated.

PVT1, an lncRNA mapped at 8q24, was demonstrated to be involved in the tumorigenesis of various cancer types. A previous study suggested that PVT1 expression was significantly higher in colorectal cancer tissues compared with that in normal tissues, and that the knockdown of PVT1 may inhibit cell proliferation ([@b30-ol-0-0-8315]). Wan *et al* ([@b13-ol-0-0-8315]) additionally revealed that PVT1 promoted lung cancer cell proliferation through the regulation of large tumor suppressor kinase 2. Various studies additionally revealed that PVT1 influenced the expression of MYC ([@b14-ol-0-0-8315],[@b31-ol-0-0-8315]). All these reports indicated that PVT1 may be involved in cancer pathophysiology ([@b32-ol-0-0-8315]). However, to the best of our knowledge, no previous study has reported the expression pattern and biological function of PVT1 in ccRCC.

In the present study, the association between PVT1 expression and ccRCC was investigated. PVT1 was revealed to be significantly upregulated in ccRCC tissues compared with that in adjacent normal tissues (P\<0.001). Furthermore, high PVT1 expression was associated with advanced ccRCC stage. The results demonstrated that PVT1 expression was significantly associated with age (P=0.018). PVT1 expression in patients ≥60 years old was significantly higher compared with that in patients \<60 years old. Survival analysis revealed that the overall survival time was significantly shorter in the high PVT1 expression group compared with that in the low PVT1 expression group (P\<0.01). It was hypothesized that the association between PVT1 expression and age affected the survival analysis to a certain extent. Although PVT1 expression is associated with age, PVT1 expression may be an independent prognostic factor for patients with ccRCC. Furthermore, the findings were confirmed by TCGA database, as its cohort size was large enough and the follow-up time was long enough to draw a conclusion without substantial bias, and it demonstrated that the survival time of patients with high PVT1 expression was shorter compared with that of patients with low PVT1 expression. The results revealed that PVT1 expression was significantly associated with T stage (P\<0.001) and M stage (P=0.024), but not with tumor grade. Tumor grading is a measure of cell differentiation and is based on the resemblance of the tumor to the tissue of origin. Tumor grading is distinguished from staging, which is a measure of the extent to which the cancer has spread ([@b33-ol-0-0-8315]). This finding may be due to the fact that PVT1 serves an important role in the cell cycle and cell proliferation, which are associated with advanced T stage and M stages. Additionally, the differentiation of RCC cells was not markedly affected by PVT1, resulting in non-significant differences between PVT1 expression and tumor grade. All these results suggested that PVT1 may promote the tumorigenesis of ccRCC.

To elucidate how PVT1 affects the biological behavior of ccRCC cells, a series of experiments was designed to evaluate the biological function of PVT1. It was revealed that the knockdown of PVT1 induced cell apoptosis and promoted cell cycle arrest at the G1 phase. The mitochondria-mediated intrinsic pathway and the death receptor-induced extrinsic pathway are the major pathways for the regulation of cell apoptosis ([@b34-ol-0-0-8315],[@b35-ol-0-0-8315]). Bax is a key component for cellular induced apoptosis, which increases the permeability of the mitochondrial membrane and results in the activation of the caspase pathway for apoptosis ([@b36-ol-0-0-8315]). Western blotting in the present study revealed that the knockdown of PVT1 increased the level of Bax and the cleavage of PARP, a marker of cells undergoing apoptosis ([@b37-ol-0-0-8315]). Therefore, the results of the present study indicated that the knockdown of PVT1 induced cell apoptosis through the mitochondria-dependent pathway. In addition, the knockdown of PVT1 induced cell cycle arrest at the G1 phase by regulating the level of cyclin D1, which is an important protein for controlling cell transition through the G1 phase into the DNA synthesis S phase ([@b38-ol-0-0-8315]).

EGFR family members are involved in the mechanisms of cell proliferation and apoptosis, and the cell cycle ([@b39-ol-0-0-8315]--[@b41-ol-0-0-8315]). EGFR signaling may regulate the biological behavior of cancer cells through AKT, MAPK and numerous other pathways ([@b42-ol-0-0-8315]). In the present study, it was revealed that silencing PVT1 decreased the expression of EGFR and its downstream protein AKT, and p-AKT. Research has also indicated that MYC expression is regulated by the EGFR family ([@b43-ol-0-0-8315]). The expression of MYC was confirmed and it was revealed that the expression of MYC was decreased subsequent to the silencing of PVT1. Therefore, it was concluded that PVT1 activated the EGFR pathway and participated in the progression of ccRCC.

In conclusion, the present study demonstrated that PVT1 expression was significantly upregulated in ccRCC compared with that in normal tissues, and that the high expression of PVT1 was associated with advanced stage and a poor prognosis. Results also indicated that the knockdown of PVT1 induced the apoptosis and cell cycle arrest of ccRCC cells through activation of the EGFR pathway. These findings indicate that PVT1 may serve as a novel therapeutic target in ccRCC.
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![Survival with regard to PVT1 gain. Patients with PVT1 gain experienced a significantly shorter overall survival time compared with those without PVT1 gain. P\<0.01 vs. WT. PVT1, Pvt1 oncogene (non-protein coding); WT, wild-type.](ol-15-05-7855-g00){#f1-ol-0-0-8315}

![Upregulation of PVT1 in ccRCC. (A) Relative PVT1 expression in 40 pairs of ccRCC and paired adjacent tissues was detected using reverse transcription-quantitative polymerase chain reaction. (B) Mean expression of PVT1 in ccRCC tissues and adjacent normal tissues (\*P\<0.05 vs. normal) tissues. (C) Expression of PVT1 in ccRCC tissues and normal tissues from The Cancer Genome Atlas (\*P\<0.05 vs. normal). (D) Patients with high PVT1 expression experienced significantly shorter overall survival times compared with the low PVT1 expression group. Data are presented as the mean ± standard deviation. PVT1, Pvt1 oncogene (non-protein coding); ccRCC, clear cell renal cell carcinoma.](ol-15-05-7855-g01){#f2-ol-0-0-8315}

![Knockdown of PVT1 inhibits proliferation, induces apoptosis and promotes cell cycle arrest in ccRCC cells. (A) Expression of PVT1 in ccRCC cells and normal kidney cells (\*P\<0.05 vs. HK-2). (B) si-PVT1 significantly decreased the expression of PVT1 in 786O and Caki-1 cells compared with cells transfected with si-NC (\*P\<0.05 vs. NC). (C) Knockdown of PVT1 inhibited cell proliferation. Cell proliferation was detected using the MTS method (\*P\<0.05 vs. NC). (D) Knockdown of PVT1 induced apoptosis. Apoptosis was detected by flow cytometry (\*P\<0.05 vs. NC) (\*P\<0.05 si-PVT1a vs. si-PVT1b in 786-O). (E) Knockdown of PVT1 resulted in cell cycle arrest at the G1 phase. Cell cycle was detected using flow cytometry (\*P\<0.05 vs. NC). Data are shown as the mean ± standard deviation. PVT1, Pvt1 oncogene (non-protein coding); ccRCC, clear cell renal cell carcinoma; si-PVT1, small interfering RNA for PVT1; NC, negative control; OD, optical density.](ol-15-05-7855-g02){#f3-ol-0-0-8315}

![Knockdown of PVT1 increases the expression of cleaved PARP, Bax and P21 and decreased the expression of cyclin D1 compared with the NC groups. β-tubulin was used as a reference gene. PVT1, Pvt1 oncogene (non-protein coding); si-PVT1, small interfering RNA for PVT1; NC, negative control; PARP, poly ADP ribose polymerase; Bax, Bcl-2-associated X protein; p21, cyclin-dependent kinase inhibitor 1A.](ol-15-05-7855-g03){#f4-ol-0-0-8315}

![PVT1 regulates the activation of the EGFR pathway in clear cell renal cell carcinoma cells. (A) Reverse transcription-quantitative polymerase chain reaction examined the mRNA expression of EGFR, AKT and MYC following PVT1-knockdown (\*P\<0.05 vs. NC). (B) Western blotting examined the protein expression of EGFR, AKT, p-AKT and MYC following PVT1-knockdown. GADPH was used as the reference gene. PVT1, Pvt1 oncogene (non-protein coding); EGFR, epidermal growth factor receptor; AKT, protein kinase B; MYC, MYC proto-oncogene, BHLH transcription factor; p-, phosphorylated; NC, negative control.](ol-15-05-7855-g04){#f5-ol-0-0-8315}

###### 

Association between Pvt1 oncogene (non-protein coding) expression and clinical characteristics of patients with clear cell renal cell carcinoma.

  Characteristics   n     Expression   F-value   P-value
  ----------------- ----- ------------ --------- ----------------------------------------------------
  Sex                                  0.982     0.322
    Male            288   0.656                  
    Female          160   0.759                  
  Age, years                           5.633     0.018^[a](#tfn1-ol-0-0-8315){ref-type="table-fn"}^
    \<60            205   0.566                  
    ≥60             243   0.800                  
  T stage                              17.90     \<0.001a
    T1-2            276   0.530                  
    T3-4            172   0.953                  
  M stage                              5.102     0.024^[a](#tfn1-ol-0-0-8315){ref-type="table-fn"}^
    M0              376   0.644                  
    M1              72    0.947                  
  N stage                              2.934     0.088
    N0              218   0.594                  
    N1              16    1.084                  
    NX              214   0.766                  
  Tumor grade                          0.017     0.895
    G1-2            208   0.706                  
    G3-4            235   0.693                  
    GX              5     0.162                  
  AJCC stage                           14.78     \<0.001a
    I               215   0.477                  
    II              46    0.626                  
    III             112   0.966                  
    IV              75    0.942                  

P\<0.05 was considered to indicate a statistically significant difference. AJCC, american joint committee on cancer.
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